Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumor Grade 3 × surufatinib × Endocrine × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 9 Carcinoma, Neuroendocrine 2 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Pancreatic Neoplasms 1 Neuroendocrine Tumor Grade 3 1 Neoplasm Metastasis 1 Differentiated Thyroid Cancer 1 Colorectal Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡